ABUS - Arbutus Biopharma Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.10
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.10
Open9.05
Bid7.60 x 1800
Ask9.05 x 3100
Day's Range9.00 - 9.23
52 Week Range3.45 - 12.60
Volume162,465
Avg. Volume485,826
Market Cap504.179M
Beta2.11
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateMay 2, 2018 - May 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.32
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis

    Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company's lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, Inc. (ALNY), announced that their new drug application (NDA) for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. Because ONPATTRO is enabled by our proprietary LNP technology, this approval triggers a royalty to Arbutus and provides us with important non-dilutive revenue to support our HBV cure mission, through several important clinical milestones next year,” said Dr. Mark Murray, Arbutus’ President and CEO.

  • GlobeNewswire9 days ago

    Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference

    WARMINSTER, Pa., Aug. 09, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, ...

  • GlobeNewswire16 days ago

    Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update

    -Phase 1 a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated. -Phase 1 a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of ...

  • ACCESSWIRE16 days ago

    Arbutus Biopharma Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Arbutus Biopharma Corporation (NASDAQ: ABUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...

  • ContraVir Stock Rose on Clinical Trial Progress Report
    Market Realist25 days ago

    ContraVir Stock Rose on Clinical Trial Progress Report

    On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.

  • Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
    Zacks29 days ago

    Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)

  • Harry Boxer’s three drug stocks to watch
    MarketWatchlast month

    Harry Boxer’s three drug stocks to watch

    Drug stocks are dominating our list of top charts to watch. Arbutus Biopharma Corp. (ABUS) snapped back 55 cents to $11.35 on 417,300 shares traded Tuesday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped 65 cents to $16.45 on 1 million shares traded Tuesday.

  • GlobeNewswirelast month

    Arbutus to Report Second Quarter 2018 Financial Results

    WARMINSTER, Pa., July 19, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it has scheduled its second quarter financial results, ...

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks get even hotter?

  • Harry Boxer’s four health-care stocks to watch
    MarketWatchlast month

    Harry Boxer’s four health-care stocks to watch

    In focus: Arbutus Biopharma, Marinus Pharmaceuticals, Neptune Technologies & Bioressources and OPKO Health.

  • GlobeNewswirelast month

    Arbutus Presents Corporate Update on Key Milestones

    The first subject has been dosed in a clinical trial of AB-506, Arbutus’ second-generation capsid inhibitor. The regulatory filing for AB-452, Arbutus’ novel and proprietary RNA destabilizer, is on track for submission in Q3, with subject dosing to follow in Q4. Study completion is expected by Q3 2019.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks keep the momentum going?

  • Benzingalast month

    Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run

    Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally.   The Analyst B. Riley FBR's ...

  • Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%
    Zackslast month

    Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%

    Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    Arbutus Biopharma to Present at First Annual Roivant Pipeline Day

    Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. A live webcast will be available via the Investors section, under Events and Presentations of Arbutus' website at www.arbutusbio.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. Roivant Pipeline Day will be held on Tuesday, July 10, 2018, in New York City.

  • GlobeNewswire2 months ago

    Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer

    Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June 11, 2018.  Mr. Hastings will assume the CFO role from Koert VandenEnden, Arbutus' interim Chief Financial Officer. "We’re excited to welcome David Hastings to Arbutus as our new CFO," said Dr. Mark J Murray, CEO of Arbutus.

  • GlobeNewswire2 months ago

    Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diodes ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib

    LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.

  • Associated Press4 months ago

    Arbutus: 1Q Earnings Snapshot

    The Burnaby, British Columbia-based company said it had a loss of 36 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...